Cargando…

Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells

Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira-Oliveira, Maria, Reis-Mendes, Ana, Carvalho, Félix, Remião, Fernando, Bastos, Maria de Lourdes, Costa, Vera Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/
https://www.ncbi.nlm.nih.gov/pubmed/30634681
http://dx.doi.org/10.3390/biom9010021
_version_ 1783392113094819840
author Pereira-Oliveira, Maria
Reis-Mendes, Ana
Carvalho, Félix
Remião, Fernando
Bastos, Maria de Lourdes
Costa, Vera Marisa
author_facet Pereira-Oliveira, Maria
Reis-Mendes, Ana
Carvalho, Félix
Remião, Fernando
Bastos, Maria de Lourdes
Costa, Vera Marisa
author_sort Pereira-Oliveira, Maria
collection PubMed
description Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake). Concerning the equimolar combination with 1 or 5 μM, FAC caused similar cytotoxicity to DOX alone. Even in the presence of higher concentrations of 5-FU and CYA (50 μM 5-FU + 1 μM DOX + 50 μM CYA), 1 μM DOX was still a determinant for the cardiotoxicity observed in the cytotoxicity assays, phase contrast morphological evaluation, and mitochondrial potential depolarization evaluation. To the best of our knowledge, this was the first in vitro work with this combination regimen, DOX being the most toxic drug and key to the toxicity of FAC.
format Online
Article
Text
id pubmed-6358964
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63589642019-02-11 Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells Pereira-Oliveira, Maria Reis-Mendes, Ana Carvalho, Félix Remião, Fernando Bastos, Maria de Lourdes Costa, Vera Marisa Biomolecules Article Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake). Concerning the equimolar combination with 1 or 5 μM, FAC caused similar cytotoxicity to DOX alone. Even in the presence of higher concentrations of 5-FU and CYA (50 μM 5-FU + 1 μM DOX + 50 μM CYA), 1 μM DOX was still a determinant for the cardiotoxicity observed in the cytotoxicity assays, phase contrast morphological evaluation, and mitochondrial potential depolarization evaluation. To the best of our knowledge, this was the first in vitro work with this combination regimen, DOX being the most toxic drug and key to the toxicity of FAC. MDPI 2019-01-10 /pmc/articles/PMC6358964/ /pubmed/30634681 http://dx.doi.org/10.3390/biom9010021 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pereira-Oliveira, Maria
Reis-Mendes, Ana
Carvalho, Félix
Remião, Fernando
Bastos, Maria de Lourdes
Costa, Vera Marisa
Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title_full Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title_fullStr Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title_full_unstemmed Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title_short Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
title_sort doxorubicin is key for the cardiotoxicity of fac (5-fluorouracil + adriamycin + cyclophosphamide) combination in differentiated h9c2 cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358964/
https://www.ncbi.nlm.nih.gov/pubmed/30634681
http://dx.doi.org/10.3390/biom9010021
work_keys_str_mv AT pereiraoliveiramaria doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells
AT reismendesana doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells
AT carvalhofelix doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells
AT remiaofernando doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells
AT bastosmariadelourdes doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells
AT costaveramarisa doxorubiciniskeyforthecardiotoxicityoffac5fluorouraciladriamycincyclophosphamidecombinationindifferentiatedh9c2cells